Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive non-small cell lung cancer. The third-generation (3G) EGFR-TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Bin-Chi, Lin, Chia-Chi, Lee, Jih-Hsiang, Yang, James Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135794/
https://www.ncbi.nlm.nih.gov/pubmed/27912760
http://dx.doi.org/10.1186/s12929-016-0305-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135794/
https://www.ncbi.nlm.nih.gov/pubmed/27912760
http://dx.doi.org/10.1186/s12929-016-0305-9

Ejemplares similares